Stockscreener 앱 받기
1.22
2.52%
0.03
시간 외 거래:
1.22
Repare Therapeutics Inc 주식(RPTX)의 최신 뉴스
Repare Therapeutics Stock Hits 52-Week Low at $1.2 Amid Market Challenges - MSN
Repare Therapeutics (RPTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
Repare Therapeutics (RPTX) Stock Price, News & Analysis - MarketBeat
Repare Therapeutics (RPTX) Loses -5.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
CNL Partners With Repare And Defence Therapeutics For Cancer Research - Canadian Manufacturing
CNL'S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Financial Post
CNL’S CNRI-H Program Continues Strong Growth Thanks to New Projects With Repare Therapeutics and Defence Therapeutics - Yahoo Finance
Short Interest in Repare Therapeutics Inc. (NASDAQ:RPTX) Grows By 53.3% - MarketBeat
Repare Therapeutics eyes Phase III cancer study after Mythic trial success - MSN
The Market Doesn't Like What It Sees From Repare Therapeutics Inc.'s (NASDAQ:RPTX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Repare Therapeutics Announces Strategic Changes and Financial Update - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Acquired by Barclays PLC - Defense World
Stifel cuts Repare Therapeutics target to $3, maintains Buy By Investing.com - Investing.com Canada
Repare Therapeutics stock rating cut to Hold at Bloom Burton By Investing.com - Investing.com Canada
Repare Therapeutics Shifts Focus to Phase 1 Programs - TipRanks
Repare cans plans for phase 3 cancer combo trial in latest money-saving move - Fierce Biotech
Repare Therapeutics Seeks Partner Before Advancing Cancer Treatment - MarketWatch
Repare Therapeutics Streamlines Pipeline, Extends Cash Runway to 2027 with Strategic Restructuring - StockTitan
Eton Pharmaceuticals (NASDAQ:ETON) versus Repare Therapeutics (NASDAQ:RPTX) Financial Survey - Defense World
Repare Therapeutics Inc. (NASDAQ:RPTX) Shares Purchased by Stifel Financial Corp - Defense World
Repare Therapeutics stock hits 52-week low at $1.22 - Investing.com
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector - Baystreet.ca
Stifel Nicolaus Has Lowered Expectations for Repare Therapeutics (NASDAQ:RPTX) Stock Price - Defense World
Lifesci Capital Reiterates Market Perform Rating for Repare Therapeutics (NASDAQ:RPTX) - Defense World
Repare Therapeutics (NASDAQ:RPTX) Given "Market Perform" Rating at Lifesci Capital - MarketBeat
LifeSci Capital Downgrades Repare Therapeutics (RPTX) - MSN
Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
Why Is Repare Therapeutics Stock Trading Lower On Friday? - Yahoo Finance
Drug duo to Repare lack in gyno cancers? Phase I shows promise - BioWorld Online
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results - Yahoo Finance
Repare Therapeutics stock hits 52-week low at $2.35 - Investing.com
Stifel Nicolaus Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $4.00 - MarketBeat
Press Release Service: Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - CRISPR Medicine News
Promising trial results for Repare's cancer drug combo - Investing.com India
Repare stock tanks 38% after Phase 1 data release - MSN
Promising trial results for Repare's cancer drug combo By Investing.com - Investing.com UK
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial - Business Wire
Press Release Service: Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - CRISPR Medicine News
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial - BioSpace
UK desirability has turned a corner in clinical trials - Yahoo Finance
3.95%
2.39%
자본화:
|
볼륨(24시간):